Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by InvrsContrarianon Feb 18, 2021 10:27pm
228 Views
Post# 32606433

RE:We can expect a lot more...!

RE:We can expect a lot more...!So from what we know is that most biotech companies trade 10-15 times P/E. With a solid 1.5 mill from 3rd quarter we can speculate that the 4th quarter will be slighter higher than that from the available info from Tripp. I think we are still undervalued from that one quarter (the 3rd period lol) alone by a 2 million Mkt cap shortage. Now bring out the big guns and watch the 4th quarter(sunden death overtime) report shoot us upwards.. Things are on track, Milestone being reached and the valuations are correct. I'd like to see a P/E of 25 for the ground breaking work being release with the Aristotle concept . The market owes us that at least. Such a risky endeavour but with great risk comes great rewards.
RelevantStock wrote:
We have broken out of the 1.10 zone (and other levels after) with rapid buys of around 500-700k shares at most. I am expecting days with volume at least at 3-5M, maybe more, when we make the news for the launch of Aristotle, partnerships, revenue, etc. So happy of how we held this morning (and yesterday morning too). The new buyers here just arrived early for the front row tickets, much more to come.


<< Previous
Bullboard Posts
Next >>